Absci (ABSI) Revenue & Revenue Breakdown
Absci Revenue Highlights
Latest Revenue (Y)
$5.72M
Latest Revenue (Q)
$898.00K
Absci Revenue by Period
Absci Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $5.72M | -0.50% |
2022-12-31 | $5.75M | 20.18% |
2021-12-31 | $4.78M | 0.04% |
2020-12-31 | $4.78M | 132.04% |
2019-12-31 | $2.06M | - |
Absci Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $898.00K | 165.68% |
2023-12-31 | $338.00K | -54.57% |
2023-09-30 | $744.00K | -77.90% |
2023-06-30 | $3.37M | 165.33% |
2023-03-31 | $1.27M | -18.50% |
2022-12-31 | $1.56M | -34.28% |
2022-09-30 | $2.37M | 136.43% |
2022-06-30 | $1.00M | 22.34% |
2022-03-31 | $819.00K | -43.60% |
2021-12-31 | $1.45M | -5.65% |
2021-09-30 | $1.54M | 111.40% |
2021-06-30 | $728.00K | -31.51% |
2021-03-31 | $1.06M | -61.03% |
2020-12-31 | $2.73M | 197.82% |
2020-09-30 | $916.00K | 62.41% |
2020-06-30 | $564.00K | -1.40% |
2020-03-31 | $572.00K | - |
Absci Revenue Breakdown
Absci Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Jun 21 |
---|---|
Collaborative Revenue | $136.00K |
Technology Development Revenue | $592.00K |
Latest
Absci Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Jun 21 |
---|---|
Collaborative Revenue | $136.00K |
Technology Development Revenue | $592.00K |
Latest
Absci Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
DTIL | Precision BioSciences | $48.73M | $576.00K |
RXRX | Recursion Pharmaceuticals | $44.58M | $14.42M |
CRBU | Caribou Biosciences | $34.48M | $3.46M |
RLAY | Relay Therapeutics | $25.55M | - |
AFMD | Affimed | $8.28M | $155.00K |
ABSI | Absci | $5.72M | $898.00K |
XFOR | X4 Pharmaceuticals | - | $560.00K |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
ZURA | Zura Bio | - | - |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
ELEV | Elevation Oncology | - | - |
SANA | Sana Bio | - | - |
HEPA | Hepion Pharmaceuticals | - | - |